Fig. 4: PFS and OS with durvalumab–ceralasertib and with durvalumab plus olaparib, danvatirsen or oleclumab in HUDSON in patient subgroups.
Figure shows medians and 80% CI per Kaplan–Meier methodology.
Fig. 4: PFS and OS with durvalumab–ceralasertib and with durvalumab plus olaparib, danvatirsen or oleclumab in HUDSON in patient subgroups. | Nature Medicine